Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1797]

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced...

Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced rectal cancer ( Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2...

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment ( Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA )

Pembro plus chemo followed by resection and adjuvant pembro improves on...

Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA

Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC ( Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA )

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab...

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active...

Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL ( Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for...

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

Optimising cervical cancer care in Nigeria

Prof Don Dizon - Rhode Island Hospital, Rhode Island, USA

Optimising cervical cancer care in Nigeria ( Prof Don Dizon - Rhode Island Hospital, Rhode Island, USA )

More from ecancer